Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 4,247 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease
Interventions: Sodium zirconium cyclosilicate, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 29
States / cities: Florence, Alabama • Chula Vista, California • Downey, California + 25 more

Conditions: Alzheimer Disease
Interventions: Simvastatin; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 50 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Autism, Autism Spectrum Disorder
Interventions: Adderall XR (mixed salts amphetamine), Placebo; Drug
Lead sponsor: Gagan Joshi; Other
Eligibility: 8 Years to 18 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions: Everolimus (RAD001), Everolimus Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 6
States / cities: Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Bicifadine; Drug
Lead sponsor: XTL Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Paducah, Kentucky

Conditions: Diabetes Mellitus
Interventions: Pioglitazone and azilsartan, Pioglitazone; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 704 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 64
States / cities: Birmingham, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 61 more

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions: ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®); Genetic · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 107
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more

Conditions: Macular Degeneration
Interventions: NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks; Drug
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more

Conditions: Osteoporosis, Postmenopausal Osteoporosis
Interventions: Placebo, BA058 80 mcg, teriparatide; Drug
Lead sponsor: Radius Health, Inc.; Industry
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 2,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Lakewood, Colorado • Miami, Florida • North Miami, Florida + 2 more

Conditions: Ocular Myasthenia Gravis
Interventions: Rozanolixizumab, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Scottsdale, Arizona • O'Fallon, Illinois • Amherst, New York + 3 more

Conditions: Respiratory Distress Syndrome (RDS)
Interventions: LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube); Combination Product · Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 30 Minutes to 24 Hours
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 26
States / cities: Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more

Conditions: Hip Surgery Corrective, Anesthesia; Functional
Interventions: Drug group Fascia iliaca nerve block, Control group sham nerve block; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Use, Pain, Marijuana Use
Interventions: Cannabis, Prescription Opioid Taper Support (POTS); Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Portland, Maine • Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Sleep, Sleep Disturbance, Sleep Disorder
Interventions: Radicle Rest Placebo Control Form 1, Radicle Rest Active Study Product 1.1 Usage, Radicle Rest Placebo Control Form 2, Radicle Rest Active Study Product 2.1 Usage, Radicle Rest Placebo Control 4.1.0, Radicle Rest Active Study Product 4.1.1 Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,646 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Smoking, Bipolar Disorder
Interventions: Experimental plus Nicotine Replacement Therapy, Control plus Nicotine Replacement Therapy; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Palo Alto, California • Denver, Colorado • Bedford, Massachusetts + 1 more

Conditions: PTSD, Alcohol Abuse, Alcoholism
Interventions: Topiramate, Placebo administration; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1999
U.S. locations: 11
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more

Conditions: Transplant Associated Microangiopathy TAM
Interventions: LFG316 active drug, Standard of care treatment; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Columbus, Ohio

Conditions: Tobacco Use Disorder
Interventions: Brief Negotiated Interview (BNI), Nicotine replacement therapy (NRT), CT Smokers Quitline (QL), SmokefreeText (Text); Behavioral · Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetic Foot, Peripheral Arterial Disease
Interventions: PDA-002, Placebo; Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson's Disease
Interventions: AFQ056 with L-dopa, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana + 1 more

Conditions: Acute Pain
Interventions: Diclofenac Sodium Patch, Matching Placebo Patch; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 17 Years to 75 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Non-alcoholic Steatohepatitis
Interventions: MGL-3196, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 26
States / cities: Dothan, Alabama • Tucson, Arizona • Coronado, California + 23 more

Conditions: Anthrax
Interventions: Ciprofloxacin and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim; Drug · Other
Lead sponsor: PharmAthene, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study

The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain

Radicle Rest 24: A Study of Health and Wellness Products on Sleep and Related Health Outcomes

Web-Delivered Acceptance & Commitment Therapy for Smokers With Bipolar Disorder

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients

Optimizing Tobacco Dependence Treatment in the Emergency Department

Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Ph1 Study of Valortim and Ciprofloxacin in Humans